Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
IBRX

IBRX - ImmunityBio, Inc. Stock Price, Fair Value and News

$6.15+0.20 (+3.36%)
Market Closed

10/100

IBRX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

10/100

IBRX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$5.16

Target 3M

$5.81

Target 6M

$5.48

IBRX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

IBRX Price Action

Last 7 days

-11.1%

Last 30 days

201.5%

Last 90 days

160.6%

Trailing 12 Months

99.7%

IBRX RSI Chart

IBRX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

IBRX Valuation

Market Cap

6.1B

Price/Earnings (Trailing)

-17.38

Price/Sales (Trailing)

73.38

EV/EBITDA

-24.76

Price/Free Cashflow

-18.65

IBRX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$5.16

Target 3M

$5.81

Target 6M

$5.48

IBRX Fundamentals

IBRX Revenue

Revenue (TTM)

82.6M

Rev. Growth (Yr)

425.07%

Rev. Growth (Qtr)

21.33%

IBRX Earnings

Earnings (TTM)

-348.6M

Earnings Growth (Yr)

21.55%

Earnings Growth (Qtr)

27.35%

IBRX Profitability

EBT Margin

-422.38%

Return on Equity

-296.98%

Return on Assets

-67.18%

Free Cashflow Yield

-5.36%

IBRX Investor Care

Shares Dilution (1Y)

41.35%

Diluted EPS (TTM)

-0.4

IBRX Alerts

  • 2 major insider sales recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202531.2M56.6M82.6M0
20244.2M7.7M11.2M14.7M
2023586.0K592.0K556.0K622.0K
2022760.5K587.0K413.5K240.0K
2021687.3K769.5K851.8K934.0K
20202.4M2.6M2.8M605.0K
2019585.8K1.1M1.7M2.2M
20182.0M1.4M701.5K47.0K
20173.0M2.9M2.8M2.7M
20163.0M3.1M3.1M3.1M
2015475.0K384.0K364.0K3.0M
2014610.3K620.5K630.8K641.0K
2013000600.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About ImmunityBio, Inc.

IBRX
ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that complement, harness, and amplify the immune system to defeat cancers and infectious diseases in the United States and Europe. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion protein N-803, vaccine technologies, toll-Like receptor activating adjuvants, natural killer cells, and damage-associated molecular patterns inducers. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute and Amyris, Inc.; and license agreements with LadRx Corporation, GlobeImmune, Inc., Access to Advanced Health Institute, 3M Innovative Properties Company, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company is based in San Diego, California.
 CEO
 WEBSITEhttps://immunitybio.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES683

ImmunityBio, Inc. Frequently Asked Questions

IBRX is the stock ticker symbol of ImmunityBio, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of ImmunityBio, Inc. is 6.06 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check IBRX's fair value in chart for subscribers.

The fair value guage provides a quick view whether IBRX is over valued or under valued. Whether ImmunityBio, Inc. is cheap or expensive depends on the assumptions which impact ImmunityBio, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for IBRX.

As of Wed Jan 28 2026, IBRX's PE ratio (Price to Earnings) is -17.38 and Price to Sales (PS) ratio is 73.38. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. IBRX PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, ImmunityBio, Inc. has provided -0.05 (multiply by 100 for percentage) rate of return.